157 related articles for article (PubMed ID: 15081595)
1. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
3. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Schilling G; Coonfield ML; Ross CA; Borchelt DR
Neurosci Lett; 2001 Nov; 315(3):149-53. PubMed ID: 11716985
[TBL] [Abstract][Full Text] [Related]
4. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
[TBL] [Abstract][Full Text] [Related]
6. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
7. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
8. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
9. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
10. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Huntington Study Group
Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
[TBL] [Abstract][Full Text] [Related]
12. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.
Klevytska AM; Tebbenkamp AT; Savonenko AV; Borchelt DR
J Neuropathol Exp Neurol; 2010 Apr; 69(4):396-404. PubMed ID: 20448484
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
Norflus F; Nanje A; Gutekunst CA; Shi G; Cohen J; Bejarano M; Fox J; Ferrante RJ; Hersch SM
Neurobiol Dis; 2004 Nov; 17(2):319-25. PubMed ID: 15474369
[TBL] [Abstract][Full Text] [Related]
14. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
15. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.
Hickey MA; Zhu C; Medvedeva V; Franich NR; Levine MS; Chesselet MF
Mol Cell Neurosci; 2012 Feb; 49(2):149-57. PubMed ID: 22044764
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
17. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
[TBL] [Abstract][Full Text] [Related]
18. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
[TBL] [Abstract][Full Text] [Related]
19. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
[TBL] [Abstract][Full Text] [Related]
20. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
